HLA class II genes confer the strongest genetic risk to develop RA
Neurological disorders, such as numbness of the limbs and tingling feelings have been reported, as well as psychological symptoms, generally seen through mood disorders
The peptide was originally identified by Loren Pickart in 1973 in human plasma and has since been characterized in saliva, urine, and tissue
Recent studies have documented the presence of LBs and -syn deposits in multiple other peripheral locations, including the retina, olfactory epithelium, salivary glands, cardiac sympathetic nerves, adrenal glands, and skin [75, 91, 92]
Clinical Benefits (Evidence-Based): Increased lean muscle mass (average 4-6% improvement in studies) Reduced body fat, particularly abdominal fat (8-12% reduction) Improved sleep quality and deeper REM cycles Enhanced recovery from exercise and injury Better skin elasticity and reduced wrinkles Improved bone density markers Enhanced cognitive function and mental clarity Dosing Protocols: Typically administered subcutaneously before bed, 5-7 days per week